Dr. Petrylak on the Role of Docetaxel in mHSPC

Partner | Cancer Centers | <b>Yale Cancer Center</b>

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, professor of medicine and urology and co-leader of Cancer Signaling Networks with Yale Cancer Center, as well as a 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer ​(mHSPC).

​The open-label, phase 3 ENZAMET trial ​randomized men with mHSPC to testosterone suppression plus enzalutamide (Xtandi) or a standard nonsteroidal anti​androgen. Results showed that enzalutamide was associated with significantly longer progression-free and overall survival (OS) compared with standard therapy in this patient population. Similar findings were demonstrated in the ​phase 3 LATITUDE and STAMPEDE trials, Petrylak says.

However, unlike the LATITUDE and STAMPEDE trials, ENZAMET allowed patients to received prior docetaxel. Although it ​is understood that docetaxel does not improve the OS benefit associated with enzalutamide, future research efforts must determine whether docetaxel is needed, Petrylak concludes.